Baseline Productions

Baseline Productions Short-term Debt

The Short-Term Debt of Baseline Productions (BSSP) as of Nov 15, 2026 is 495,200.00 USD. In the previous year, Short-Term Debt was 494,000.00 USD — a change of 0.24% (higher).

Short-term Debt

495,200.00USD

YoY

0.24%

Last updated:

Short-Term Debt of Baseline Productions is 2020 495,200.00 USD. Short-Term Debt of Baseline Productions was 2019 494,000.00 USD. It decreases by 0.24% higher compared to the previous year.

The Baseline Productions Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2014
249,118.00 USD
Jan 1, 2019
494,000.00 USD
Jan 1, 2020
495,200.00 USD
The Baseline Productions Short-term Debt history
YEARShort-term DebtYoY
495,200.00USD+0.24%
494,000.00USD+98.30%
249,118.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Short-Term Debt of Baseline Productions is 495,200.00 USD in 2020.

Short-Term Debt of Baseline Productions changed from 494,000.00 USD to 495,200.00 USD, representing a 0.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Baseline Productions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Baseline Productions

All Key Metrics — Baseline Productions